What the FDA's Revised PAI Guidance Means for Change Control

On June 29, 2026, FDA issued a revised Compliance Program Guide governing Pre-Approval Inspections: FDA Compliance Program 7346.832 with an effective date of August 10, 2026. On the surface, this reads like routine housekeeping: FDA periodically updates the internal playbooks its investigators use to prepare for and conduct PAIs. But the substance of this revision signals something more consequential for manufacturers of drugs, biologics, and devices with pending applications.

The updated guidance does three things worth paying close attention to. First, it embeds ICH Q12 "Established Conditions" thinking directly into how investigators assess a facility's readiness. Second, it deepens the scrutiny applied to change control systems specifically, not just whether changes were documented, but whether the system managing them can be trusted going forward. Third, it formalizes Remote Regulatory Assessments (RRAs) as a legitimate, documented alternative or complement to the traditional on-site visit.

Individually, none of these are brand-new concepts. ICH Q12 has been shaping post approval change management thinking since 2021. RRAs have been part of FDA's toolkit since the pandemic. What's new is that all three are now formally woven into the compliance program investigators use for PAI decision-making. This means they are no longer optional considerations for manufacturers preparing approval-track inspections.

"Established Conditions", as defined under ICH Q12, are the elements of a product manufacturing process and controls considered necessary to ensure product quality. In practice, an EC framework tells a regulator and tells the manufacturer itself exactly which parameters can shift without triggering a regulatory filing, and which changes require one.

Embedding EC concepts into the PAI compliance program means investigators are now oriented to ask a sharper question than "were changes documented?" They're asking whether a facility can clearly articulate which conditions are established, why, and how its change control system enforces that boundary in practice. A manufacturer with a well-defined EC framework can answer that question cleanly.

This is a meaningful shift in what "inspection-ready" means. It's no longer sufficient to have clean batch records and a tidy deviation log. The FDA is now assessing whether the underlying governance structure is sound enough to be trusted without a physical walkthrough every time.

Formalizing Remote Regulatory Assessments as a PAI-adjacent tool changes the practical shape of inspection readiness. An RRA typically involves FDA requesting electronic records, production documentation, and virtual interviews or livestream walkthroughs rather than sending investigators on-site. That means a manufacturer's data package — their ability to produce organized, traceable, and complete documentation on demand — is now nearly as important to inspection outcomes as the physical state of the facility itself.

This has real operational implications. Electronic batch records, validation summaries, and change control histories need to be structured for remote review, not just internal audit. Facilities that have historically treated documentation systems as a compliance formality, rather than a presentation-ready asset, will find themselves at a disadvantage if the FDA elects to substitute or supplement a PAI with an RRA.

It's worth noting that voluntary RRAs can be declined without violating the FD&C Act. But a refusal can delay FDA's ability to act on a pending application, which, for any manufacturer racing toward an approval decision, is not really a viable option. In practice, being RRA-ready is becoming table stakes.

Three capabilities separate organizations that will move through this transition smoothly from those that will get caught flat-footed:

None of these are quick fixes assembled in the weeks before a PAI. They're the product of a change control system and quality infrastructure built to hold up under scrutiny at any time, which is precisely the posture this guidance update is designed to reward.

For organizations preparing for a PAI or reassessing their posture in light of this guidance, our team works directly with quality and manufacturing leadership to design EC and change control frameworks that hold up under both on-site and remote scrutiny, build PPQ and validation plans aligned to that framework from day one, and structure data packages so a Remote Regulatory Assessment is a formality rather than a scramble.

The manufacturers best positioned for this new inspection landscape aren't the ones with the cleanest facility on the day an investigator walks in. They're the ones who can demonstrate, at any moment and through any channel FDA chooses, that their systems already know the difference between a routine adjustment and a reportable change.